Diagnosing malignant pleural effusion using clinical and analytical parameters
- PMID: 30390322
- PMCID: PMC6818593
- DOI: 10.1002/jcla.22689
Diagnosing malignant pleural effusion using clinical and analytical parameters
Abstract
Background: Malignant pleural effusion (MPE) is common and diagnosis is often problematic. A cancer ratio (serum lactate dehydrogenases: pleural adenosine deaminase ratio) has been proposed for diagnosing MPE. However, the usefulness of this "cancer ratio" and the clinical-radiological criteria for diagnosing MPE has not been clearly determined to date. The aim of this study was to assess the performance of those parameters in the diagnosis of MPE.
Methods: We analyzed 240 patients including 120 with MPE and 120 with non-MPE (93 tuberculous and 27 parapneumonic). Patients were divided into two groups: MPE and non-MPE (eg, tuberculous and parapneumonic). We constructed two predictive models to assess the probability of MPE: (a) clinical-radiological data only and (b) a combination of clinical-radiological data, the cancer ratio, and the carcinoembryonic antigen (CEA). The performances of the predictive models were assessed using receiver operating characteristic (ROC) curves and by examining the calibration.
Results: The area under the ROC curves for model 1 and model 2 were excellent, 0.936 and 0.998, respectively. The overall diagnostic accuracies for model 1 and model 2 were 87.5% and 98.8%, respectively.
Conclusion: The results confirm that both models achieved a high diagnostic accuracy for MPE; however, model 2 was superior with the addition of its simplicity of use in daily practice. This model should be applied to determine which patients with a pleural effusion of unknown origin would not benefit from further invasive procedures.
Keywords: diagnosis; lactate dehydrogenases; logistic models; malignant; pleural effusion.
© 2018 Wiley Periodicals, Inc.
Figures
Similar articles
-
Combining clinical and analytical parameters improves prediction of malignant pleural effusion.Lung. 2013 Dec;191(6):633-43. doi: 10.1007/s00408-013-9512-2. Epub 2013 Oct 2. Lung. 2013. PMID: 24085319
-
Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion.J Clin Lab Anal. 2017 Sep;31(5):e22106. doi: 10.1002/jcla.22106. Epub 2016 Dec 15. J Clin Lab Anal. 2017. PMID: 27976800 Free PMC article.
-
[The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].Zhonghua Zhong Liu Za Zhi. 2017 Jul 23;39(7):524-527. doi: 10.3760/cma.j.issn.0253-3766.2017.07.009. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28728299 Chinese.
-
Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis.Respirology. 2008 Jun;13(4):518-27. doi: 10.1111/j.1440-1843.2008.01291.x. Epub 2008 Apr 14. Respirology. 2008. PMID: 18422869
-
Diagnostic value of survivin for malignant pleural effusion: a clinical study and meta-analysis.Int J Clin Exp Pathol. 2014 Aug 15;7(9):5880-7. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25337230 Free PMC article. Review.
Cited by
-
The clinical efficacy of traditional Chinese medicine in the treatment of malignant pleural effusion: A protocol of systematic review and meta-analysis.Medicine (Baltimore). 2020 Sep 25;99(39):e22403. doi: 10.1097/MD.0000000000022403. Medicine (Baltimore). 2020. PMID: 32991466 Free PMC article.
-
Driverless artificial intelligence framework for the identification of malignant pleural effusion.Transl Oncol. 2021 Jan;14(1):100896. doi: 10.1016/j.tranon.2020.100896. Epub 2020 Oct 9. Transl Oncol. 2021. PMID: 33045678 Free PMC article.
-
Development of risk prediction models for lung cancer based on tumor markers and radiological signs.J Clin Lab Anal. 2021 Mar;35(3):e23682. doi: 10.1002/jcla.23682. Epub 2020 Dec 16. J Clin Lab Anal. 2021. PMID: 33325592 Free PMC article.
-
Diagnostic accuracy of cancer ratio for malignant pleural effusion: a systematic review and meta-analysis.Ann Transl Med. 2019 Oct;7(20):554. doi: 10.21037/atm.2019.09.85. Ann Transl Med. 2019. PMID: 31807535 Free PMC article.
-
Value of Cancer Ratio plus and Cancer Ratio Formulation in Distinguishing Malignant Pleural Effusion from Tuberculosis and Parapneumonic Effusion.Tanaffos. 2021 Mar;20(3):221-231. Tanaffos. 2021. PMID: 35382086 Free PMC article.
References
-
- Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002;346(25):1971‐1977. - PubMed
-
- Sahn SA. State of the art. The pleura. Am Rev Respir Dis. 1988;138(1):184‐234. - PubMed
-
- Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez‐Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15–3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126(6):1757‐1763. - PubMed
-
- Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE. Diagnostic value of Her‐2/neu, Cyfra 21–1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology. 2010;42(3):224‐228. - PubMed
-
- Hackbarth JS, Murata K, Reilly WM, Algeciras‐Schimnich A. Performance of CEA and CA19‐9 in identifying pleural effusions caused by specific malignancies. Clin Biochem. 2010;43(13–14):1051‐1055. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials